

Supplementary Figures and Tables




Figure S1. Receiver operating characteristic (ROC) curve of PD-1⁺CD8⁺T cells or CD38⁺CD101⁺ PD-1⁺CD8⁺ T cell percentages with the indicated clinicopathological parameters. The relationship between sensitivity and specificity of PD-1⁺CD8⁺T or PD-1⁺CD38⁺CD101⁺CD8⁺T cell percentages to discriminate clinicopathological parameters (N= N classification; M= M classification; T= T classification, T1~T2 vs. T3~T4; C= clinical stage, I~II vs. III~IV).

Tables

Table S1. Correlation of the frequency of the indicated subsets of PD-1⁺CD8⁺ T cells with major clinicopathological parameters in PDAC patients.

Clinicopathological Parameters	n	CD38 ⁺ CD101 ⁻		<i>p</i> value	CD38 ⁻ CD101 ⁺		<i>p</i> value	CD38 ⁻ CD101 ⁻		<i>p</i> value
		Low	High		Low	High		Low	High	
Age(years)				0.113			0.498			0.821
< 65	53	30	23		28	25		27	26	
≥ 65	31	12	19		14	17		15	16	
Gender				0.657			0.075			0.374
Male	50	26	24		21	29		23	27	
Female	34	16	18		21	13		19	15	
Tumor site				0.102			0.815			0.243
Head	57	25	32		29	28		26	31	
Body+Tail	27	17	10		13	14		16	11	
Histological grade				0.321			0.620			0.136
Well	22	13	9		12	10		8	14	
Poor+Moderate	62	29	33		30	32		34	28	
Tumor size(cm)				0.186			0.659			0.078
≤ 2.0	36	21	15		17	19		14	22	
>2.0	48	21	27		25	23		28	20	
Tumor classification				0.087			0.258			0.042*
T1 ~ T2	53	28	15		24	29		22	31	
T3 ~ T4	31	14	17		18	13		20	11	
Node classification				0.274			0.512			0.126
N0	39	17	22		21	18		16	23	
N1	45	25	20		21	24		26	19	
Distant metastasis				0.190			0.382			0.029*
M0	40	23	17		22	18		15	25	
M1	44	19	25		20	24		27	17	
Clinical stage(AJCC)				0.510			0.272			0.124
I ~ II	37	20	17		16	21		15	22	
III ~ IV	47	22	25		26	21		27	20	

Note: significant differences with $P < 0.05$ are indicated in bold.

Table S2. Areas under the curve (AUC), *P* value and 95% confidence interval corresponding to each subset of peripheral PD-1⁺CD8⁺T cells analyzed on ROC curve for the clinicopathological parameters discrimination.

Parameters	PD-1 ⁺ CD8 ⁺ T cell subsets	AUC	<i>P</i> value	95% CI
N classification (N0/N1)	PD-1 ⁺	0.643	0.275	0.376~0.910
	PD-1 ⁺ CD38 ⁺	0.696	0.114	0.481~0.912
	PD-1 ⁺ CD101 ⁺	0.590	0.503	0.329~0.852
	PD-1 ⁺ CD38 ⁻ CD101 ⁻	0.267	0.084	0.044~0.490
	PD-1⁺CD38⁺CD101⁺	0.879	0.006*	0.730~1.000
M classification (M0/M1)	PD-1 ⁺	0.529	0.818	0.276~0.782
	PD-1 ⁺ CD38 ⁺	0.858	0.005*	0.705~1.000
	PD-1 ⁺ CD101 ⁺	0.642	0.262	0.406~0.877
	PD-1 ⁺ CD38 ⁻ CD101 ⁻	0.158	0.007*	0.000~0.346
	PD-1⁺CD38⁺CD101⁺	0.990	<0.001*	0.958~1.000
T classification (T1~T2/T3~T4)	PD-1 ⁺	0.496	0.974	0.240~0.752
	PD-1 ⁺ CD38 ⁺	0.736	0.032*	0.552~0.920
	PD-1 ⁺ CD101 ⁺	0.575	0.553	0.321~0.829
	PD-1 ⁺ CD38 ⁻ CD101 ⁻	0.258	0.056	0.032~0.485
	PD-1⁺CD38⁺CD101⁺	0.950	0.001*	0.848~1.000
Clinical stage (I~II/III~IV)	PD-1 ⁺	0.615	0.352	0.368~0.862
	PD-1 ⁺ CD38 ⁺	0.779	0.087	0.608~0.949
	PD-1 ⁺ CD101 ⁺	0.551	0.657	0.331~0.772
	PD-1 ⁺ CD38 ⁻ CD101 ⁻	0.273	0.043*	0.084~0.461
	PD-1⁺CD38⁺CD101⁺	0.831	0.008*	0.657~1.000

Note: AUC were compared for each subset studied, in order to determine the marker(s) with the best discriminable capacity on PDAC clinicopathological parameters. The 95% CI and the *P*-value are derived from testing the hypothesis that the associated AUC is not different from 0.5 (random classification). The level of statistical significance was set at *P* < 0.05. The highest values of AUC, which are associated with the best accuracy, which are indicated in bold. PD-1⁺CD38⁺CD101⁺T cell percentages had the best discriminatory capacity on T classification, N classification, M classification and clinical stage of PDAC.